

**Recommendations of the SEC (Antimicrobial & Antiparasitic) made in its 07<sup>th</sup>/26 meeting held on 09.07.2026 at CDSCO HQ New Delhi:**

| S. No               | File Name & Drug Name, Strength                                          | Firm Name                 | Recommendations                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>GCT Division</b> |                                                                          |                           |                                                                                                                                                                                                                                                                                                                                                                                  |
| 1.                  | CT/92/26<br>Online Submission<br>(57520)<br><br>Cefepime +<br>Zidebactam | M/s. Wockhardt<br>Limited | The firm presented phase III clinical study protocol no. W-5222-302 amendment 2, version no. 3.0 dated 27-MAY-2026.<br><br>After detailed deliberation, the committee recommended for grant of permission to conduct the trial as presented by the firm with condition that more government sites who is equipped with Bio-fire testing facility shall be included in the study. |